Veristat

Veristat

Founded in 1994 in Massachusetts, Veristat built its practice around full-service clinical trial management and regulatory consulting for biotechnology and pharmaceutical companies. The firm operates as an independent CRO, not a family office, and does not invest its own capital in client programs — its revenue is fee-for-service from drug developers who need monitoring, data management, medical writing, and strategic regulatory advice for FDA and EMA submissions. Veristat's engagement model covers clinical development phases I–IV, statistical programming, and post-marketing surveillance. The firm has reported involvement in programs that led to regulatory approvals in therapeutic areas including oncology, rare disease, and neurology. Its geographic execution footprint includes North America, Western Europe, Israel, and East Asia, reflecting the multinational trial sites required by its sponsors. Veristat competes with other mid-market CROs such as PPD and ICON, differentiating on project-team continuity and a consultant-heavy staffing model. The firm is privately held, headquartered in Southborough, Massachusetts, with smaller satellite offices established over time to support regional trial monitoring needs. No ownership or governance structure changes have been publicly disclosed. Veristat publishes thought leadership on regulatory landscapes — including FDA fast-track designations and EU medical-device regulation transitions — through its own content channels. Veristat's structural differentiator lies in combining a CRO with a standalone strategic-consulting unit that advises on regulatory pathway design, a split that gives sponsors an integrated view of trial execution and approval strategy under one engagement. This consulting-led CDMO-adjacent posture has been copied by few peers at its scale, and the firm trades on that integration when competing for niche oncology and rare disease programs.